Gilead faces lawsuit over hepatitis C drug pricing


Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

HAVERFORD, Pa. (AP) — Philadelphia's Transportation Authority has filed a lawsuit against Gilead Sciences Inc. over the pricing of its hepatitis C drug.

Sovaldi is a highly effective pill treatment for the most common form of hepatitis C without the injections and unpleasant side effects of earlier treatments.

Gilead has been selling a 12-week treatment of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. That has raised complaints by insurers, politicians and patient advocates, particularly because millions of Americans could benefit from the drug.

The complaint was filed in federal court. It says Sovaldi's cost prohibits many patients from getting treatment and accuses Gilead of "unjust enrichment" that violates antitrust law.

The Foster City, California, company could not be reached immediately for a comment Wednesday.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.
    Newsletter Signup

    KSL Weather Forecast

    KSL Weather Forecast
    Play button